Automated Breast Ultrasound System Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Automated Breast Ultrasound System (ABUS), Automated Breast Volume Scanner (ABVS), By Modality (Standalone, Portable), By End Users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers) and Region Forecast 2019-2030

Automated Breast Ultrasound System Market size was valued at US$ 1,844.6 million in 2023 and is poised to grow at a CAGR of 10.5% from 2024-2030. An automated breast ultrasound system (ABUS) is a medical imaging technology designed specifically for breast imaging. It's a supplementary tool used alongside traditional mammography to enhance the detection and evaluation of breast abnormalities, especially in women with dense breast tissue. ABUS provides a 3D ultrasound image of the breast, offering a more detailed view of breast tissue compared to conventional 2D mammography.

The rising incidence of breast cancer plays a significant role in driving the demand for the automated breast ultrasound system (ABUS). Each year, breast cancer affects over 2.3 million adults, making it the most common type of cancer worldwide, as reported by the World Health Organization. As the global prevalence of breast cancer continues to increase, there is a growing need for more effective and accurate screening methods. ABUS fulfills this demand by offering a supplementary imaging tool that enhances the detection of breast abnormalities, especially in women with dense breast tissue. Moreover, the improved breast cancer detection capability of automated breast ultrasound systems is a significant driver of the market. ABUS functions by providing high-resolution 3D ultrasound images that offer a more detailed view of breast tissue.

These detailed images enhance the visibility of abnormalities that might be difficult to detect through mammography alone. As healthcare providers and patients recognize the potential for ABUS to improve early cancer detection, there is a growing demand for this advanced imaging technology.However, ABUS systems can be expensive to acquire and maintain. The initial investment, along with ongoing operational costs, can be a barrier for healthcare facilities, particularly those with limited budgets. Meanwhile, continued research and clinical trials exploring the effectiveness of ABUS in various patient populations can create significant opportunities for the growth of the automated breast ultrasound systems market. Key manufacturers are continuously involved in research and development processes to innovate advanced solutions to cater to the healthcare industries. For instance, in May 2022, iSono Health, Inc. announced U.S. Food and Drug Administration (FDA) clearance of ATUSA System for breast imaging, a first-of-its-kind compact automated whole breast ultrasound system.

Key Developments

• In March 2023, MetriTrack Inc. and SST Group Inc. collaborated to distribute and support Breast Volume Navigator, BVN G-2000, a computer-assisted breast ultrasound solution to imaging clinics across the Midwest.
• In November 2018, GE Healthcare launched the Invenia Automated Breast Ultrasound (ABUS) 2.0 system in the United States.